RxDoctor Payments Data

Kritzia Pineda Monroy, MD

Internal Medicine · Oakland Park, FLNPI 1679922520

Payments from drug & device makers

$2,101in general payments, 2019–2025

Across 59 payments — averaging $35.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$781
  • Gilead$358
  • Pfizer$204
  • Novo Nordisk$141
  • Nevro Corp.$124
  • Sanofi-aventis U.S. LLC$119
  • plus $374 from 10 others

What the payments were for

  • Food & beverage$2,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,101 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$144,067
Medicare patients
354
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$104,891
MounjaroTirzepatide95$104,431
JardianceEmpagliflozin76$92,112
JanuviaSitagliptin Phosphate28$34,704
EliquisApixaban20$24,110
XareltoRivaroxaban14$20,667
TrulicityDulaglutide11$15,745
Breo ElliptaFluticasone/Vilanterol23$12,231
Atorvastatin Calcium620$6,118
Rosuvastatin Calcium382$5,550
Levothyroxine Sodium483$4,834
Valsartan178$4,232
Amlodipine Besylate546$3,249
Losartan Potassium325$3,234
SynthroidLevothyroxine Sodium38$2,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$97$120,177106 claims
Novo NordiskOzempic$141$104,89183 claims
Boehringer IngelheimJardiance$13$92,11276 claims
PfizerEliquis$204$24,11020 claims
Johnson & JohnsonXarelto$67$20,66714 claims
GSKBreo Ellipta$21$12,23123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Oakland Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →